Cargando…
Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expre...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739211/ https://www.ncbi.nlm.nih.gov/pubmed/31534629 http://dx.doi.org/10.18632/oncotarget.27145 |
_version_ | 1783450901753626624 |
---|---|
author | Bonk, Sarah Kluth, Martina Hube-Magg, Claudia Polonski, Adam Soekeland, Greta Makropidi-Fraune, Georgia Möller-Koop, Christina Witt, Melanie Luebke, Andreas M. Hinsch, Andrea Burandt, Eike Steurer, Stefan Clauditz, Till S. Schlomm, Thorsten Perez, Daniel Graefen, Markus Heinzer, Hans Huland, Hartwig Izbicki, Jakob R. Wilczak, Waldemar Minner, Sarah Sauter, Guido Simon, Ronald |
author_facet | Bonk, Sarah Kluth, Martina Hube-Magg, Claudia Polonski, Adam Soekeland, Greta Makropidi-Fraune, Georgia Möller-Koop, Christina Witt, Melanie Luebke, Andreas M. Hinsch, Andrea Burandt, Eike Steurer, Stefan Clauditz, Till S. Schlomm, Thorsten Perez, Daniel Graefen, Markus Heinzer, Hans Huland, Hartwig Izbicki, Jakob R. Wilczak, Waldemar Minner, Sarah Sauter, Guido Simon, Ronald |
author_sort | Bonk, Sarah |
collection | PubMed |
description | To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9–100% (1:800–1:100) primary tumors, 98.7–99.7% of advanced recurrent cancers, in 84.6–91.4% castration resistant cancers, and in 7.7–18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0–3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0–1 of 21 thyroid gland carcinomas and 0–1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined “PSA pattern score” was built from staining intensity and pattern. The prognostic impact of the “PSA pattern score” was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions. |
format | Online Article Text |
id | pubmed-6739211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-67392112019-09-18 Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues Bonk, Sarah Kluth, Martina Hube-Magg, Claudia Polonski, Adam Soekeland, Greta Makropidi-Fraune, Georgia Möller-Koop, Christina Witt, Melanie Luebke, Andreas M. Hinsch, Andrea Burandt, Eike Steurer, Stefan Clauditz, Till S. Schlomm, Thorsten Perez, Daniel Graefen, Markus Heinzer, Hans Huland, Hartwig Izbicki, Jakob R. Wilczak, Waldemar Minner, Sarah Sauter, Guido Simon, Ronald Oncotarget Research Paper To assess the prognostic and diagnostic utility of PSA immunostaining, tissue microarrays containing 17,747 prostate cancers, 3,442 other tumors from 82 different (sub) types and 608 normal tissues were analyzed at two different antibody concentrations (1:100 and 1:800). In normal tissues, PSA expression was limited to prostate epithelial cells. In prostate cancers, PSA staining was seen in 99.9–100% (1:800–1:100) primary tumors, 98.7–99.7% of advanced recurrent cancers, in 84.6–91.4% castration resistant cancers, and in 7.7–18.8% of 16 small cell carcinomas. Among extraprostatic tumors, PSA stained positive in 0–3 (1:800-1:100) of 19 osteosarcomas, 1-2 of 34 ovarian cancers, 0-2 of 35 malignant mesotheliomas, 0–1 of 21 thyroid gland carcinomas and 0–1 of 26 large cell lung cancers. Reduced staining intensity and loss of apical staining were strongly linked to unfavorable tumor phenotype and poor prognosis (p < 0.0001 each). This was all the more the case if a combined “PSA pattern score” was built from staining intensity and pattern. The prognostic impact of the “PSA pattern score” was independent of established pre- and postoperative clinico-pathological prognostic features. In conclusion, PSA immunostaining is a strong prognostic parameter in prostate cancer and has high specificity for prostate cancer at a wide range of antibody dilutions. Impact Journals LLC 2019-09-10 /pmc/articles/PMC6739211/ /pubmed/31534629 http://dx.doi.org/10.18632/oncotarget.27145 Text en Copyright: © 2019 Bonk et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Bonk, Sarah Kluth, Martina Hube-Magg, Claudia Polonski, Adam Soekeland, Greta Makropidi-Fraune, Georgia Möller-Koop, Christina Witt, Melanie Luebke, Andreas M. Hinsch, Andrea Burandt, Eike Steurer, Stefan Clauditz, Till S. Schlomm, Thorsten Perez, Daniel Graefen, Markus Heinzer, Hans Huland, Hartwig Izbicki, Jakob R. Wilczak, Waldemar Minner, Sarah Sauter, Guido Simon, Ronald Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues |
title | Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues |
title_full | Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues |
title_fullStr | Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues |
title_full_unstemmed | Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues |
title_short | Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues |
title_sort | prognostic and diagnostic role of psa immunohistochemistry: a tissue microarray study on 21,000 normal and cancerous tissues |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739211/ https://www.ncbi.nlm.nih.gov/pubmed/31534629 http://dx.doi.org/10.18632/oncotarget.27145 |
work_keys_str_mv | AT bonksarah prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT kluthmartina prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT hubemaggclaudia prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT polonskiadam prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT soekelandgreta prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT makropidifraunegeorgia prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT mollerkoopchristina prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT wittmelanie prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT luebkeandreasm prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT hinschandrea prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT burandteike prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT steurerstefan prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT clauditztills prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT schlommthorsten prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT perezdaniel prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT graefenmarkus prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT heinzerhans prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT hulandhartwig prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT izbickijakobr prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT wilczakwaldemar prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT minnersarah prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT sauterguido prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues AT simonronald prognosticanddiagnosticroleofpsaimmunohistochemistryatissuemicroarraystudyon21000normalandcanceroustissues |